Management of Skin Toxicities from Multikinase Inhibitor Therapies

The information on the site is not country-specific, and may contain information that is outside the approved indications in the country in which you are located.

This site contains information and education for healthcare professionals and patients.

Healthcare Professionals Patients and Caregivers

This section contains information, treatment algorithms and educational materials for healthcare professionals (HCPs) relating to the management of dermatological toxicities in patients treated with multikinase inhibitors.

Access now

By pursuing, you confirm that you have read and understand the disclaimer.

This site contains information on skin, mouth and hair changes (known as adverse reactions) that can sometimes occur for patients receiving the following cancer treatments only: Stivarga® (regorafenib), Nexavar® (sorafenib), Caprelsa® (vandetanib), Sutent® (sunitinib), Glivec® (imatinib). Here, we aim to bring you important information on how you can work with your doctor/nurse to manage skin, mouth and hair adverse reactions to your cancer treatment.

Access Now

By pursuing, you confirm that you have read and understand the disclaimer.